emindole SB beta-mannoside | 1537895-69-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: emindole SB beta-mannoside
• 英文别名: (2R,3S,4S,5S,6R)-2-(hydroxymethyl)-6-[[(1S,12S,15R,16S,17S,20S)-1,16,20-trimethyl-16-(4-methylpent-3-enyl)-3-azapentacyclo[10.8.0.02,10.04,9.015,20]icosa-2(10),4,6,8-tetraen-17-yl]oxy]oxane-3,4,5-triol
• CAS: 1537895-69-4
• 化学式: C₃₄H₄₉NO₆
• 分子量: 567.766
• InChiKey: RLMHLVYKLURACD-CHRYWTOVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  41
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  115
• 氢给体数：
  5
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  emindole SB beta-mannoside 在 盐酸 作用下， 以 水 为溶剂， 反应 5.0h， 生成 D-甘露糖 、 beta-D-吡喃甘露糖 、 β-L-mannopyranose 、 D-吡喃葡萄糖 、 Emindole SB
  参考文献：
  名称：

  Indoloditerpenes from a Marine-Derived Fungal Strain of Dichotomomyces cejpii with Antagonistic Activity at GPR18 and Cannabinoid Receptors

  摘要：

  A marine-derived strain of Dichotomomyces cejpii produces the new compounds emindole SB beta-mannoside (1) and 27-O-methylasporyzin C (2), as well as the known indoloditerpenes JBIR-03 (3) and emindole SB (4). Indo le derivative 1 was found to be a CB2 antagonist, while 2 was identified as the first selective GPR18 antagonist with an indole structure. Compound 4 was found to be a nonselective CB1/CB2 antagonist. The new natural indole derivatives may serve as lead structures for the development of GPR18- and CB receptor-blocking drugs.

  DOI：

  10.1021/np400850g

文献信息

• Indoloditerpenes from a Marine-Derived Fungal Strain of <i>Dichotomomyces cejpii</i> with Antagonistic Activity at GPR18 and Cannabinoid Receptors
  作者：Henrik Harms、Viktor Rempel、Stefan Kehraus、Marcel Kaiser、Peter Hufendiek、Christa E. Müller、Gabriele M. König

  DOI：10.1021/np400850g

  日期：2014.3.28

  A marine-derived strain of Dichotomomyces cejpii produces the new compounds emindole SB beta-mannoside (1) and 27-O-methylasporyzin C (2), as well as the known indoloditerpenes JBIR-03 (3) and emindole SB (4). Indo le derivative 1 was found to be a CB2 antagonist, while 2 was identified as the first selective GPR18 antagonist with an indole structure. Compound 4 was found to be a nonselective CB1/CB2 antagonist. The new natural indole derivatives may serve as lead structures for the development of GPR18- and CB receptor-blocking drugs.